Allach Youssra, Banda Amina, van Gemert Willemijn, de Groot Michel, Derks Yvonne, Schilham Melline, Hoepping Alexander, Perk Lars, Gotthardt Martin, Janssen Marcel, Nagarajah James, Privé Bastiaan M
Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands.
Department of Cardiology, Erasmus MC, 3015 CE Rotterdam, The Netherlands.
Cancers (Basel). 2022 Apr 21;14(9):2076. doi: 10.3390/cancers14092076.
Positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) allows for accurate diagnosis and staging of prostate cancer (PCa). Compared to other PSMA PET tracers available, [18F]PSMA-1007 is predominantly excreted via the hepatobiliary tract resulting in low renal excretion which improves evaluation of the pelvic area. However, some patients do show high urinary uptake of [18F]PSMA-1007. The present study aimed to investigate this sudden high urinary uptake of [18F]PSMA-1007 by evaluating [18F]PSMA-1007 PET scans from PCa patients. In this single-center retrospective study, patients that underwent [18F]PSMA-1007 PET imaging between July 2018 and January 2021 were included. Data regarding the individual patient characteristics, scan acquisition and batch production were analyzed. To determine the urinary excretion of [18F]PSMA-1007, a region of interest was drawn in the bladder, and standardized uptake values (SUVs) were calculated and compared to SUVs in the prostate. An SUVmax of >10 was considered high urinary excretion, an SUVmax 7.5−10 intermediate and an SUVmax < 7.5 low urinary excretion. A total of 344 patients underwent [18F]PSMA-1007 PET/CT imaging, with 37 patients receiving three or more [18F]PSMA-1007 PET/CT scans. The mean SUVmean and SUVmax of the bladder were 3.9 (SD 2.9) and 5.9 (SD 4.2), respectively. Fourteen percent of patients showed high urinary uptake of [18F]PSMA-1007. Twelve of the thirty-seven patients (32.4%) that had multiple scans showed a varying urinary uptake of [18F]PSMA-1007 per PSMA PET/CT scan. In terms of patient characteristics, risk factors, medication and blood laboratory results, no significant influencing variables were found. Nor was there a difference observed in the batch size and the mean radiochemical purity of PSMA-1007 for high- and low-excreting patients. However, the bladder volume affected the mean SUVmax in the bladder significantly, with higher SUVs in lower bladder volumes. In this study, we observed that a higher SUV in the urinary tract seemed to occur in patients with low bladder volume. A prospective study is needed to corroborate this hypothesis.
前列腺特异性膜抗原(PSMA)正电子发射断层扫描(PET)有助于前列腺癌(PCa)的准确诊断和分期。与其他可用的PSMA PET示踪剂相比,[18F]PSMA - 1007主要通过肝胆系统排泄,导致肾脏排泄量低,这改善了盆腔区域的评估。然而,一些患者确实表现出[18F]PSMA - 1007的高尿液摄取。本研究旨在通过评估PCa患者的[18F]PSMA - 1007 PET扫描来调查[18F]PSMA - 1007突然出现的高尿液摄取情况。在这项单中心回顾性研究中,纳入了2018年7月至2021年1月期间接受[18F]PSMA - 1007 PET成像的患者。分析了有关个体患者特征、扫描采集和批量生产的数据。为了确定[18F]PSMA - 1007的尿液排泄情况,在膀胱中绘制感兴趣区域,并计算标准化摄取值(SUV),并与前列腺中的SUV进行比较。SUVmax>10被认为是高尿液排泄,SUVmax 7.5 - 10为中等,SUVmax<7.5为低尿液排泄。共有344例患者接受了[18F]PSMA - 1007 PET/CT成像,其中37例患者接受了三次或更多次[18F]PSMA - 1007 PET/CT扫描。膀胱的平均SUVmean和SUVmax分别为3.9(标准差2.9)和5.9(标准差4.2)。14%的患者表现出[18F]PSMA - 1007的高尿液摄取。在进行多次扫描的37例患者中,有12例(32.4%)在每次PSMA PET/CT扫描中表现出[18F]PSMA - 1007的尿液摄取变化。在患者特征、风险因素、药物治疗和血液实验室结果方面,未发现显著的影响变量。高排泄和低排泄患者在PSMA - 1007的批量大小和平均放射化学纯度方面也没有差异。然而,膀胱体积对膀胱中的平均SUVmax有显著影响,膀胱体积越小,SUV越高。在本研究中,我们观察到尿路中较高的SUV似乎出现在膀胱体积较小的患者中。需要进行前瞻性研究来证实这一假设。